{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:53:56Z","timestamp":1765731236608,"version":"3.48.0"},"reference-count":19,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016288","name":"Kissei","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019271","name":"Kyorin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,2,27]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Overactive bladder (OAB) is a condition characterised by urinary urgency, often accompanied by frequency and nocturia. Antimuscarinics and \u03b23 receptor agonists are first-line therapies that improve urinary symptoms and the quality of life. For insufficient antimuscarinic response, options include dose increase, switching medications or combination therapy. However, evidence for these strategies, especially combinations with vibegron, is limited and needs further study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The study is designed as a randomised, open-label, parallel-group, multicentre trial conducted in Japan. A total of 110 patients with OAB who met the OAB criteria and did not respond adequately to the initial 4-week antimuscarinic treatment will be randomised in a 1:1 ratio into two groups: an add-on group in which vibegron 50\u2009mg\/day is added to the current antimuscarinic drug and a switch group in which the current antimuscarinics are discontinued and replaced with vibegron 50\u2009mg\/day\u2060. The primary endpoint is the intergroup comparison of changes in daily urinary frequency between the add-on group and the switch group at 12 weeks after the initiation of protocol treatment. The primary analysis aims to confirm the non-inferiority of the switch group compared with the add-on group using a Bayesian mixed model for repeated measures. Non-inferiority will be confirmed if the posterior probability that the difference in the change in urinary frequency at 12 weeks between the two groups falls within the non-inferiority margin of one-time is 80% or greater.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial has been reviewed and approved by the Institute of Science Tokyo Certified Clinical Research Review Board (approval number: NR2024-001)\u2060. Participants will provide informed consent to participate before taking part in the study. Results will be reported in a separate publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Japan Registry of Clinical Trials (jRCT) (jRCTs031240134)\u2060.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-094230","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T03:18:24Z","timestamp":1742872704000},"page":"e094230","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Add-on or switch to vibegron in patients with overactive bladder insufficiently responding to initial 4-week antimuscarinics: a randomised, parallel-group, multicentre trial (\n                    <b>ADVISR<\/b>\n                    )\n                    <b>protocol<\/b>"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6403-8719","authenticated-orcid":false,"given":"Takanobu","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Urology, Tokyo Metropolitan Tama-Nambu Chiiki Hospital, Tama, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Urology, Institute of Science Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Maezawa","sequence":"additional","affiliation":[{"name":"Urology, Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tamiya","sequence":"additional","affiliation":[{"name":"Urology, Japanese Red Cross Saitama Hospital, Saitama, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Toide","sequence":"additional","affiliation":[{"name":"Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Urology, Institute of Science Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Uehara","sequence":"additional","affiliation":[{"name":"Urology, Showa General Hospital, Kodaira, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Araki","sequence":"additional","affiliation":[{"name":"Urology, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Ito","sequence":"additional","affiliation":[{"name":"Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Urology, Japanese Red Cross Saitama Hospital, Saitama, Saitama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yoshinaga","sequence":"additional","affiliation":[{"name":"Urology, Soka Municipal Hospital, Soka, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Kawamura","sequence":"additional","affiliation":[{"name":"Urology, JA Toride Medical Center, Toride, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Takazawa","sequence":"additional","affiliation":[{"name":"Urology, Tokyo Metropolitan Ohtsuka Hospital, Toshima-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Sakai","sequence":"additional","affiliation":[{"name":"Urology, Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Ootsuka","sequence":"additional","affiliation":[{"name":"Urology, Japanese Red Cross Oomori Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Urology, Showa General Hospital, Kodaira, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsushi","family":"Nagahama","sequence":"additional","affiliation":[{"name":"Urology, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Urology, Institute of Science Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kitabayashi","sequence":"additional","affiliation":[{"name":"Clinical Biostatistics, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Hanazawa","sequence":"additional","affiliation":[{"name":"Clinical Biostatistics, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Health Science Research and Development Center, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Sato","sequence":"additional","affiliation":[{"name":"Clinical Biostatistics, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Koike","sequence":"additional","affiliation":[{"name":"Health Science Research and Development Center, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Fujii","sequence":"additional","affiliation":[{"name":"Urology, Institute of Science Tokyo, Bunkyo, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"2025121408512688000_15.3.e094230.1","first-page":"266","article-title":"Epidemiologic survey on lower urinary tract symptoms in Japan","volume":"14","author":"Honma","year":"2003","journal-title":"J Jpn Continence Soc"},{"key":"2025121408512688000_15.3.e094230.2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003985","article-title":"The AUA\/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder","volume":"212","author":"Cameron","year":"2024","journal-title":"J Urol"},{"key":"2025121408512688000_15.3.e094230.3","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13847","article-title":"Shifting the treatment paradigm in idiopathic overactive bladder","volume":"75","author":"Sahai","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2025121408512688000_15.3.e094230.4","unstructured":"The japanese continence society and the japanese urological association committee clinical guidelines for overactive bladder syndrome."},{"key":"2025121408512688000_15.3.e094230.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.02.012"},{"key":"2025121408512688000_15.3.e094230.6","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13882"},{"key":"2025121408512688000_15.3.e094230.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.030"},{"key":"2025121408512688000_15.3.e094230.8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"2025121408512688000_15.3.e094230.9","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13068"},{"key":"2025121408512688000_15.3.e094230.10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.13868","article-title":"Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study)","volume":"26","author":"Yamaguchi","year":"2019","journal-title":"Int J Urol"},{"key":"2025121408512688000_15.3.e094230.11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2018.10.006","article-title":"Vibegron (RVT-901\/MK-4618\/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial","volume":"75","author":"Mitcheson","year":"2019","journal-title":"Eur Urol"},{"key":"2025121408512688000_15.3.e094230.12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/iju.13596","article-title":"Long-term safety and efficacy of the novel \u03b23 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study","volume":"25","author":"Yoshida","year":"2018","journal-title":"Int J Urol"},{"key":"2025121408512688000_15.3.e094230.13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/luts.12417","article-title":"Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01","volume":"14","author":"Tachikawa","year":"2022","journal-title":"Low Urin Tract Symptoms"},{"key":"2025121408512688000_15.3.e094230.14","unstructured":"Japan registry of clinical trials (jRCT). n.d. Available: https:\/\/jrct.niph.go.jp\/latest-detail\/jRCTs031240134"},{"key":"2025121408512688000_15.3.e094230.15","unstructured":"Japan clinical oncology group (jcog), common terminology criteria for adverse events (ctcae) version 5.0. n.d. Available: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"2025121408512688000_15.3.e094230.16","unstructured":"MedDRA japanese maintenance organization (jmo). n.d. Available: https:\/\/www.meddra.org\/how-to-use\/support-documentation"},{"key":"2025121408512688000_15.3.e094230.17","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1002\/nau.24505","article-title":"A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study)","volume":"39","author":"Ko","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"2025121408512688000_15.3.e094230.18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.tcmj.2014.05.008","article-title":"Use of the International Prostate Symptom Score voiding-to-storage subscore ratio in assessing lower urinary tract symptoms","volume":"26","author":"Liao","year":"2014","journal-title":"Tzu Chi Medical Journal"},{"key":"2025121408512688000_15.3.e094230.19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00192-012-1818-8","article-title":"International Prostate Symptom Score for assessing lower urinary tract dysfunction in women","volume":"24","author":"Hsiao","year":"2013","journal-title":"Int Urogynecol J"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-094230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:51:34Z","timestamp":1765731094000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-094230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,24]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjopen-2024-094230"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-094230","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}